{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:12:28Z","timestamp":1761005548820,"version":"build-2065373602"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>We present a case of Pure Red Cell Aplasia (PRCA) secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a human immunodeficiency virus (HIV)-positive patient. To our knowledge, this is the first reported case of SARS-CoV-2-associated PRCA in an HIV-positive individual. The patient received immunosuppressive therapy (IST):initial treatment with corticosteroids was later switched to cyclosporine A (CsA), and he ultimately achieved complete remission. Additionally, we reviewed previously reported cases of SARS-CoV-2-associated PRCA. These findings emphasize that hematological abnormalities should also be recognized as a critical extrapulmonary complication of SARS-CoV-2 infection. In conclusion, SARS-CoV-2 infection can affect bone marrow tissue, leading to a spectrum of hematological abnormalities and subsequent clinical sequelae. For HIV-positive patients presenting with PRCA, antiretroviral drugs and acute or chronic infections should be prioritized in the diagnostic workup.<\/jats:p>","DOI":"10.3389\/fmed.2025.1674188","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T05:22:53Z","timestamp":1760937773000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pure red cell aplasia post-SARS-CoV-2 infection: a case report in an HIV-positive patient"],"prefix":"10.3389","volume":"12","author":[{"given":"Yanli","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renjie","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3390\/ijms26030874","article-title":"Haematological manifestations of SARS-CoV-2: insights into erythropoiesis, Hepcidin regulation, and cytokine storm","volume":"26","author":"Parham","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.1007\/s00277-024-06052-9","article-title":"Aplastic Anemia in the light of the COVID-19 pandemic: infection, vaccination, and pathophysiologic mechanisms","volume":"103","author":"Cahuapaza-Gutierrez","year":"2024","journal-title":"Ann Hematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1182\/bloodadvances.2022007174","article-title":"SARS-CoV-2 infection associated with aplastic anemia and pure red cell aplasia","volume":"6","author":"Lee","year":"2022","journal-title":"Blood Adv"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jiac.2021.10.018","article-title":"Pure red cell aplasia accompanied by COVID-19 successfully treated using cyclosporine","volume":"28","author":"Yamazaki","year":"2022","journal-title":"J Infect Chemother"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s13256-022-03545-x","article-title":"Acquired pure red cell aplasia after severe acute respiratory syndrome corona virus 2 infection: a case report","volume":"16","author":"Karrat","year":"2022","journal-title":"J Med Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3390\/idr14030044","article-title":"Warm autoimmune hemolytic Anemia and pure red cell aplasia during a severe COVID-19 B.1.1.7 infection","volume":"14","author":"Ghimire","year":"2022","journal-title":"Infect Dis Rep"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jiac.2023.04.002","article-title":"Exacerbation of autoimmune hemolytic anemia associated with pure red cell aplasia after COVID-19: a case report","volume":"29","author":"Kimura","year":"2023","journal-title":"J Infect Chemother"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13052-024-01700-2","article-title":"Transient erythroblastopenia of childhood after COVID-19 infection: a case report","volume":"50","author":"Rivetti","year":"2024","journal-title":"Ital J Pediatr"},{"key":"ref9","first-page":"1","article-title":"Tacrolimus treatment of pure red cell aplasia due to anti-erythropoietin antibodies induced by COVID-19 in hemodialysis patient: a case report","author":"Feng","year":"2024","journal-title":"Ann Clin Med Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3324\/haematol.11192","article-title":"Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine a. a nationwide cohort study in Japan for the PRCA collaborative study group","volume":"92","author":"Sawada","year":"2007","journal-title":"Haematologica"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1182\/blood-2016-05-717140","article-title":"Pure red cell aplasia","volume":"128","author":"Means","year":"2016","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1182\/blood.2021010898","article-title":"How I manage acquired pure red cell aplasia in adults","volume":"137","author":"Gurnari","year":"2021","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000547027","article-title":"Exploration of B- and T-cell receptor repertoires reveals distinct mechanisms in pure red cell aplasia, autoimmune hemolytic anemia, and aplastic anemia","author":"Zhang","year":"2025","journal-title":"Acta Haematol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/0002-9378(75)90919-9","article-title":"Failure of stressful stimuli to inhibit embryo implantation in the rat","volume":"121","author":"Castro-V\u00e1quez","year":"1975","journal-title":"Am J Obstet Gynecol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1097\/00002030-199908200-00023","article-title":"Reversible zidovudine-induced pure red cell aplasia","volume":"13","author":"Blanche","year":"1999","journal-title":"AIDS"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omad022","article-title":"Lamivudine induced pure red cell aplasia and HIV-1 drug resistance-associated mutations: a case report","volume":"2023","author":"Kakubu","year":"2023","journal-title":"Oxf Med Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.4102\/sajhivmed.v22i1.1271","article-title":"A case series of emtricitabine-induced pure red cell aplasia","volume":"22","author":"Manickchund","year":"2021","journal-title":"South Afr J HIV Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3390\/v15051124","article-title":"Clinical presentation of parvovirus B19 infection in adults living with HIV\/AIDS: a case series","volume":"15","author":"Mendes-de-Almeida","year":"2023","journal-title":"Viruses"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1365-2141.2008.07216.x","article-title":"Acquired pure red cell aplasia: updated review of treatment","volume":"142","author":"Sawada","year":"2008","journal-title":"Br J Haematol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/bjh.15245","article-title":"Sirolimus for the treatment of multi-resistant pure red cell aplasia","volume":"184","author":"Jiang","year":"2019","journal-title":"Br J Haematol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s00277-018-3431-5","article-title":"Successful treatment of refractory\/relapsed acquired pure red cell aplasia with sirolimus","volume":"97","author":"Long","year":"2018","journal-title":"Ann Hematol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1016\/S2352-3018(22)00092-3","article-title":"Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial","volume":"9","author":"Paton","year":"2022","journal-title":"Lancet HIV"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"103407","DOI":"10.1016\/j.retram.2023.103407","article-title":"Bone marrow alterations in COVID-19 infection: the root of hematological problems","volume":"71","author":"Zeylabi","year":"2023","journal-title":"Curr Res Transl Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1674188\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T05:22:54Z","timestamp":1760937774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1674188\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":24,"alternative-id":["10.3389\/fmed.2025.1674188"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1674188","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"article-number":"1674188"}}